Pharmacokinetics and Pharmacodynamics of β-Lactamase Inhibitors
- PMID:30589457
- DOI: 10.1002/phar.2210
Pharmacokinetics and Pharmacodynamics of β-Lactamase Inhibitors
Abstract
Novel β-lactamase inhibitors have extended the reach of new and existing β-lactams against multidrug-resistant bacteria expressing β-lactamases. The efficacy of these combination therapeutics relies on a complex two-component pharmacodynamic (PD) system where the β-lactamase inhibitor inactivates the bacterial β-lactamase enzyme and frees the companion β-lactam to act against its penicillin-binding protein target. Despite considerable investigation into the pharmacokinetics (PK) and pharmacodynamics of β-lactams, the pharmacology of their companion β-lactamase inhibitors has only recently been rigorously explored. This review describes the diversity of β-lactamase enzymes, mechanisms of enzyme inhibition, and factors impacting the efficacy of clinically available β-lactamase inhibitors. Relevant PK differences among available inhibitors and the PK/PD properties of these agents are described independently of their companion β-lactams. In the modern era of antibiotic resistance, a comprehensive understanding of the pharmacology, PK, and PD of β-lactamase inhibitors is paramount to maximizing the therapeutic efficacy of existing β-lactam/β-lactamase inhibitor combinations and protecting novel agents in the drug development pipeline.
Keywords: avibactam; clavulanate; clavulanic acid; diazabicyclooctanone; relebactam; sulbactam; tazobactam; vaborbactam.
© 2018 Pharmacotherapy Publications, Inc.
Similar articles
- Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.Karaiskos I, Galani I, Souli M, Giamarellou H.Karaiskos I, et al.Expert Opin Drug Metab Toxicol. 2019 Feb;15(2):133-149. doi: 10.1080/17425255.2019.1563071. Epub 2019 Jan 10.Expert Opin Drug Metab Toxicol. 2019.PMID:30626244Review.
- Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA.Zhanel GG, et al.Drugs. 2018 Jan;78(1):65-98. doi: 10.1007/s40265-017-0851-9.Drugs. 2018.PMID:29230684Review.
- In Vitro Activity of the New β-Lactamase Inhibitors Relebactam and Vaborbactam in Combination with β-Lactams against Mycobacterium abscessus Complex Clinical Isolates.Kaushik A, Ammerman NC, Lee J, Martins O, Kreiswirth BN, Lamichhane G, Parrish NM, Nuermberger EL.Kaushik A, et al.Antimicrob Agents Chemother. 2019 Feb 26;63(3):e02623-18. doi: 10.1128/AAC.02623-18. Print 2019 Mar.Antimicrob Agents Chemother. 2019.PMID:30642943Free PMC article.
- Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.Singh R, Kim A, Tanudra MA, Harris JJ, McLaughlin RE, Patey S, O'Donnell JP, Bradford PA, Eakin AE.Singh R, et al.J Antimicrob Chemother. 2015 Sep;70(9):2618-26. doi: 10.1093/jac/dkv132. Epub 2015 May 29.J Antimicrob Chemother. 2015.PMID:26024868
- The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.Pillar CM, Stoneburner A, Shinabarger DL, Krause KM, Nichols WW.Pillar CM, et al.Lett Appl Microbiol. 2016 Aug;63(2):96-102. doi: 10.1111/lam.12592.Lett Appl Microbiol. 2016.PMID:27221329
Cited by
- Utilizing Ceftazidime/Avibactam Therapeutic Drug Monitoring in the Treatment of Neurosurgical Meningitis Caused by Difficult-to-Treat ResistantPseudomonas aeruginosa and KPC-Producing Enterobacterales.Yasmin M, Nutman A, Wang L, Marshall S, Chen K, Wang J, Yahav D, Lupinsky L, Hujer AM, Bhimraj A, van Duin D, Li J, Bonomo RA.Yasmin M, et al.Open Forum Infect Dis. 2023 Oct 19;10(11):ofad507. doi: 10.1093/ofid/ofad507. eCollection 2023 Nov.Open Forum Infect Dis. 2023.PMID:38023540Free PMC article.
- Trends of Fixed-Dose Combination Antibiotic Consumption in Hospitals in China: Analysis of Data from the Center for Antibacterial Surveillance, 2013-2019.Wushouer H, Hu L, Zhou Y, Yang Y, Du K, Deng Y, Yan Q, Yang X, Chen Z, Zheng B, Guan X, Shi L.Wushouer H, et al.Antibiotics (Basel). 2022 Jul 15;11(7):957. doi: 10.3390/antibiotics11070957.Antibiotics (Basel). 2022.PMID:35884211Free PMC article.
- What are the optimal pharmacokinetic/pharmacodynamic targets for β-lactamase inhibitors? A systematic review.Assefa GM, Roberts JA, Mohammed SA, Sime FB.Assefa GM, et al.J Antimicrob Chemother. 2024 May 2;79(5):946-958. doi: 10.1093/jac/dkae058.J Antimicrob Chemother. 2024.PMID:38459763Free PMC article.
- A Difficult Case of Ventriculitis in a 40-Year-Old Woman with Acute Myeloid Leukemia.Rubino R, Trizzino M, Pipitò L, Sucato G, Santoro M, Maugeri R, Iacopino DG, Giammanco GM, Siragusa S, Cascio A.Rubino R, et al.Antibiotics (Basel). 2024 May 10;13(5):432. doi: 10.3390/antibiotics13050432.Antibiotics (Basel). 2024.PMID:38786160Free PMC article.
- A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxone.Jimenez-Toro I, Rodriguez CA, Zuluaga AF, Otalvaro JD, Vesga O.Jimenez-Toro I, et al.PLoS One. 2020 Dec 8;15(12):e0243365. doi: 10.1371/journal.pone.0243365. eCollection 2020.PLoS One. 2020.PMID:33290425Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical